220 related articles for article (PubMed ID: 7917546)
1. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group study.
Verweij J; Judson I; Steward W; Coleman R; Woll P; van Pottelsberghe C; van Glabbeke M; Mouridsen H
Eur J Cancer; 1994; 30A(6):842-3. PubMed ID: 7917546
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma.
Kleinerman ES; Gano JB; Johnston DA; Benjamin RS; Jaffe N
Am J Clin Oncol; 1995 Apr; 18(2):93-9. PubMed ID: 7900714
[TBL] [Abstract][Full Text] [Related]
3. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.
Fedorocko P
Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934
[TBL] [Abstract][Full Text] [Related]
4. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
[TBL] [Abstract][Full Text] [Related]
5. Liposomal MTP-PE.
Gano JB; Kleinerman ES
J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
[No Abstract] [Full Text] [Related]
6. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
[TBL] [Abstract][Full Text] [Related]
8. Liposomal MTP-PE: a promising new biologic response modifier.
Gano JB; Kleinerman ES
Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
[TBL] [Abstract][Full Text] [Related]
10. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
Macková NO; Fedorocko P
Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
[TBL] [Abstract][Full Text] [Related]
11. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
Fujimaki W; Itoh K; An T; Gano JB; Ross MI; Mansfield PF; Balch CM; Augustus LB; Karkevitch DD; Johnston D
Cancer Biother; 1993; 8(4):307-18. PubMed ID: 7804372
[TBL] [Abstract][Full Text] [Related]
12. Mifamurtide for the treatment of nonmetastatic osteosarcoma.
Ando K; Mori K; Corradini N; Redini F; Heymann D
Expert Opin Pharmacother; 2011 Feb; 12(2):285-92. PubMed ID: 21226638
[TBL] [Abstract][Full Text] [Related]
13. Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma.
Kleinerman ES; Maeda M; Jaffe N
Cancer Treat Res; 1993; 62():101-7. PubMed ID: 8096724
[TBL] [Abstract][Full Text] [Related]
14. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine.
Urba WJ; Hartmann LC; Longo DL; Steis RG; Smith JW; Kedar I; Creekmore S; Sznol M; Conlon K; Kopp WC
Cancer Res; 1990 May; 50(10):2979-86. PubMed ID: 1692252
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
[TBL] [Abstract][Full Text] [Related]
17. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma.
Meyers PA; Chou AJ
Adv Exp Med Biol; 2014; 804():307-21. PubMed ID: 24924182
[TBL] [Abstract][Full Text] [Related]
18. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
20. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
Gianan MA; Kleinerman ES
Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]